Related Experiment Video

Updated: Dec 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K

Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment

Bilal A Siddiqui1, Miao Zhang2, Louis L Pisters3

  • 1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Translational Andrology and Urology
|February 15, 2020
PubMed

Insights

Testicular germ cell tumors are highly curable in young men, with a 95% survival rate. This review covers their staging, risk, and standard chemotherapy treatments, plus new research for relapsed cases.

Area of Science:

  • Oncology
  • Urology
  • Medical Oncology

Background:

  • Testicular germ cell tumors (TGCTs) are the most common solid tumors in young men.
  • These cancers have a high cure rate, with a 5-year survival exceeding 95%.

Purpose of the Study:

  • To review the staging and risk classification of TGCTs.
  • To summarize the current standard of care for systemic chemotherapy treatment of TGCTs.
  • To highlight active areas of research, particularly for relapsed and refractory disease.

Main Methods:

  • Review of current clinical data and treatment guidelines for TGCTs.
  • Focus on chemotherapy regimens and supporting evidence.
  • Brief overview of ongoing clinical trials and investigational therapies.

Main Results:

  • TGCTs are successfully treated with chemotherapy, offering long-term survival.
  • Established treatment protocols exist for various stages and risk groups.
  • Active research is exploring novel therapies for resistant or recurrent TGCTs.

Conclusions:

  • Testicular cancer treatment is a success story in oncology.
  • Standard chemotherapy regimens are effective, but research continues for challenging cases.
  • Ongoing trials aim to improve outcomes for relapsed and refractory TGCT patients.
Keywords:
Neoplasmsgerm cell and embryonalnon-seminomatous germ cell tumorseminomatesticular germ cell tumor

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.5K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K